Guardant Health to present 25 liquid biopsy research abstracts at ESMO 2026
GH•Guardant Health will present 25 abstracts, including five rapid oral presentations, at the ESMO Congress in Madrid from October 23-27, 2026.
1. Research presentations
The findings include analyses suggesting FGFR2 amplification may identify patients with advanced gastric or gastroesophageal junction cancer who are more sensitive to bemarituzumab, and genomic complexity and changes in methylation-based assays may identify patients at risk of early progression on lorlatinib. A NADIM II analysis linked undetectable postsurgical residual disease to favorable long-term outcomes, while detectable disease identified patients at high risk of early recurrence.
